Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion

Fei Wang, Alison B. Kohan, Tammy L. Kindel, Kathryn L. Corbin, Craig S. Nunemaker, Silvana Obici, Stephen C. Woods, W. Sean Davidson and Patrick Tso
Proceedings of the National Academy of Sciences of the United States of America
Vol. 109, No. 24 (June 12, 2012), pp. 9641-9646
Stable URL: http://www.jstor.org/stable/41602716
Page Count: 6
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion
Preview not available

Abstract

Apolipoprotein A-IV (apoA-IV) is secreted by the small intestine in response to fat absorption. Here we demonstrate a potential role for apoA-IV in regulating glucose homeostasis. ApoA-IV-treated isolated pancreatic islets had enhanced insulin secretion under conditions of high glucose but not of low glucose, suggesting a direct effect of apoA-IV to enhance glucose-stimulated insulin release. This enhancement involves cAMP at a level distal to Ca²⁺ influx into the β cells. Knockout of apoA-IV results in compromised insulin secretion and impaired glucose tolerance compared with WT mice. Challenging apoA-IV⁻/⁻ mice with a high-fat diet led to fasting hyperglycemia and more severe glucose intolerance associated with defective insulin secretion than occurred in WT mice. Administration of exogenous apoA-IV to apoA-IV⁻/⁻ mice improved glucose tolerance by enhancing insulin secretion in mice fed either chow or a high-fat diet. Finally, we demonstrate that exogenous apoA-IV injection decreases blood glucose levels and stimulates a transient increase in insulin secretion in KKAy diabetic mice. These results suggest that apoA-IV may provide a therapeutic target for the regulation of glucose-stimulated insulin secretion and treatment of diabetes.

Page Thumbnails

  • Thumbnail: Page 
[9641]
    [9641]
  • Thumbnail: Page 
9642
    9642
  • Thumbnail: Page 
9643
    9643
  • Thumbnail: Page 
9644
    9644
  • Thumbnail: Page 
9645
    9645
  • Thumbnail: Page 
9646
    9646